Página principal > Artículos > Resultados de la búsqueda: Breast cancer

Artículos

  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Artículos Encontrados 134 registros  inicioanterior19 - 28siguientefinal  ir al registro: La búsqueda tardó 0.00 segundos. 
19.
17 p, 2.8 MB Metabolomics Insights into the Differential Response of Breast Cancer Cells to the Phenolic Compounds Hydroxytyrosol and Luteolin / Garcia-Guasch, Maite (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Escrich, Eduard (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Moral Cabrera, Raquel (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Duarte, Iola F. (University of Aveiro. Department of Chemistry)
The aim of this study was to investigate the effects of two phenolic compounds found in extra virgin olive oil, hydroxytyrosol (HT) and luteolin (LUT), on the metabolism of breast cancer (BC) cells of different molecular subtypes. [...]
2023 - 10.3390/molecules28093886
Molecules, Vol. 28, Issue 9 (May 2023) , art. 3886  
Registro completo - Creative Commons
20.
7 p, 537.4 KB Intraoperative irradiation in breast cancer : preliminary results in 80 patients as partial breast irradiation or anticipated boost prior to hypo-fractionated whole breast irradiation / Li, X. (Universitat Autònoma de Barcelona) ; Sanz, Javier (Hospital del Mar (Barcelona, Catalunya)) ; Argudo, Núria (Hospital del Mar (Barcelona, Catalunya)) ; Vernet-Tomas, Maria (Hospital del Mar (Barcelona, Catalunya)) ; Rodríguez, N. (Hospital del Mar (Barcelona, Catalunya)) ; Torrent, L. (Hospital del Mar (Barcelona, Catalunya)) ; Fernández-Velilla, E. (Hospital del Mar (Barcelona, Catalunya)) ; Pera, O. (Hospital del Mar (Barcelona, Catalunya)) ; Huang, Y. (Universitat Autònoma de Barcelona) ; Nicolau, P. (Hospital del Mar (Barcelona, Catalunya)) ; Jiménez, M. (Hospital del Mar (Barcelona, Catalunya)) ; Segura, M. (Hospital del Mar (Barcelona, Catalunya)) ; Algara, Manuel (Hospital del Mar (Barcelona, Catalunya))
To present the first results of intraoperative irradiation (IORT) in breast cancer with a low-energy photon system used as partial breast irradiation (PBI) or as an anticipated boost before whole breast hypo-fractionated irradiation (IORT + WBI), concerning tolerance, side effects, quality of life, and patient-reported outcomes. [...]
2021 - 10.1007/s12094-021-02728-0
Clinical & Translational Oncology, Vol. 24 (november 2021) , p. 829-835  
Registro completo - Creative Commons
21.
8 p, 1.0 MB Expression Patterns of miR181a and miR30d in Patients with Breast Cancer / Tavakolpournegari, Alireza (Islamic Azad University) ; Hashemi, Mehrdad (Islamic Azad University) ; Zare Karizi, Shohreh (Islamic Azad University) ; Matin Ahmadi, Arash (Nicolaus Copernicus University) ; Bidooki, Seyed Hesamoddin (University of Zaragoza) ; Banaei, Gooya (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
One of the important molecular pathways in breast cancer is the PTEN-PI3K-AKT pathway. Any change in the activity of the PTEN gene can alter the PI3K-AKT pathway. Moreover, there are subsets of genes and pathways their expression changes by post-transcriptional regulations. [...]
2022 - 10.18502/ijph.v51i7.10093
Iranian Journal of Public Health, Vol. 51, Num. 7 (July 2022) , p. 1594-1601  
Registro completo - Creative Commons
22.
16 p, 1.3 MB The Intricate Interplay between Cancer Stem Cells and Oncogenic miRNAs in Breast Cancer Progression and Metastasis / Tsintarakis, Antonis (National Hellenic Research Foundation) ; Papalouka, Chara (National Hellenic Research Foundation) ; Kontarini, Christina (National Hellenic Research Foundation) ; Zoumpourlis, Panagiotis (National Hellenic Research Foundation) ; Karakostis, Konstantinos (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ; Adamaki, Maria (National Hellenic Research Foundation) ; Zoumpourlis, Vassilis (National Hellenic Research Foundation)
Complex signaling interactions between cancer cells and their microenvironments drive the clonal selection of cancer cells. Opposing forces of antitumor and tumorigenic potential regulate the survival of the fittest clones, while key genetic and epigenetic alterations in healthy cells force them to transform, overcome cell senescence, and proliferate in an uncontrolled manner. [...]
2023 - 10.3390/life13061361
Life, Vol. 13 (june 2023)  
Registro completo - Creative Commons
23.
20 p, 4.1 MB High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer / Palafox, Marta (Hospital Universitari Vall d'Hebron) ; Monserrat, Laia (Hospital Universitari Vall d'Hebron) ; Bellet Ezquerra, Meritxell (Hospital Universitari Vall d'Hebron) ; Villacampa Javierre, Guillermo (Hospital Universitari Vall d'Hebron) ; Gonzalez-Perez, Abel (Universitat Pompeu Fabra) ; Oliveira, Mafalda (Hospital Universitari Vall d'Hebron) ; Brasó-Maristany, Fara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Ibrahimi, Nusaibah (University Paris-Saclay) ; Kannan, Srinivasaraghavan (Bioinformatics Institute (A*STAR)) ; Mina, Leonardo (Medica Scientia Innovation Research (MedSIR)) ; Herrera-Abreu, Maria Teresa (The Breast Cancer Now Research Centre) ; Òdena, Andreu (Hospital Universitari Vall d'Hebron) ; Sánchez-Guixé, Mònica (Hospital Universitari Vall d'Hebron) ; Capelán, Marta (Hospital Universitari Vall d'Hebron) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Bruna, Alejandra (The Institute of Cancer Research (Londres)) ; Rodríguez, Olga (Hospital Universitari Vall d'Hebron) ; Guzmán, Marta (Hospital Universitari Vall d'Hebron) ; Grueso, Judit (Hospital Universitari Vall d'Hebron) ; Viaplana, Cristina (Hospital Universitari Vall d'Hebron) ; Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron) ; Su, Faye (Novartis Pharmaceuticals) ; Lin, Kui (Genentech, Inc., South San Francisco) ; Clarke, Robert B. (Manchester Breast Centre) ; Caldas, Carlos (Cancer Research UK) ; Arribas, Joaquín V (Hospital Universitari Vall d'Hebron) ; Michiels, Stefan (University Paris-Saclay) ; García-Sanz, Alicia (Medica Scientia Innovation Research (MedSIR)) ; Turner, Nicholas C. (The Breast Cancer Now Research Centre) ; Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ; Nuciforo, Paolo (Hospital Universitari Vall d'Hebron) ; Dienstmann, Rodrigo (Hospital Universitari Vall d'Hebron) ; Verma, Chandra S. (National University of Singapore) ; Lopez-Bigas, Nuria (Institució Catalana de Recerca i Estudis Avançats) ; Scaltriti, Maurizio (Memorial Sloan-Kettering Cancer Center (Nova York, Estats Units d'Amèrica)) ; Arnedos, Monica (Inserm Unit U981 (França)) ; Saura, Cristina (Hospital Universitari Vall d'Hebron) ; Serra, Violeta (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. [...]
2022 - 10.1038/s41467-022-32828-6
Nature communications, Vol. 13 (september 2022)  
Registro completo - Creative Commons
24.
8 p, 641.4 KB Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer : Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial / Salvador Bofill, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Moreno Anton, Fernando (Hospital Clínico San Carlos (Madrid)) ; Rodriguez Sanchez, Cesar Augusto (Hospital Universitario de Salamanca-IBSAL) ; Galve Calvo, Elena (Hospital de Basurto (Bilbao, Biscaia)) ; Hernando Melia, Cristina (Hospital Clínic Universitari (València)) ; Ciruelos, Eva (Hospital Universitario 12 de Octubre (Madrid)) ; Vidal Losada, Maria (Hospital Clínic i Provincial de Barcelona) ; Jiménez-Rodriguez, Begoña (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; de la Cruz Merino, Luis (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Martínez Jañez, Noelia (Hospital Universitario Ramón y Cajal (Madrid)) ; Villanueva Vazquez, Rafael (Institut Català d'Oncologia) ; de Toro Salas, Ruben (Hospital Universitario de Jerez (Jerez de la Frontera)) ; Antón, Antonio (Hospital Universitario Miguel Servet (Saragossa)) ; Alvarez Lopez, Isabel Manuela (Biodonostia Osasun Ikerketako Institutura (País Basc)) ; Gavila Gregori, Joaquin (Fundació Institut Valencià d'Oncologia) ; Quiroga Garcia, Vanesa (Institut Català d'Oncologia) ; Vicente Rubio, Elena (Hospital Universitario Insular de Gran Canaria) ; de la Haba Rodríguez, Juan Rafael (Universidad de Córdoba) ; Gonzalez-Santiago, Santiago (Hospital Universitario San Pedro de Alcántara) ; Diaz Fernandez, Nieves (Hospital Universitario San Juan de Alicante) ; Barnadas i Molins, Agustí (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Cantos Sanchez de Ibargüen, Blanca (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Delgado Mingorance, Juan Ignacio (Hospital Universitario Infanta Cristina) ; Bellet Ezquerra, Meritxell (Vall d'Hebron Institut d'Oncologia) ; de Casa, Sonia (Novartis Farmacèutica, SA) ; Gimeno, Asuncion (Novartis Farmacèutica, SA) ; Martin, Miguel (Hospital General Universitario Gregorio Marañón) ; Universitat Autònoma de Barcelona
Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women. Ribociclib in combination with endocrine therapy (ET) has shown superiority in prolonging survival in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) vs. [...]
2022 - 10.1016/j.breast.2022.09.006
Breast, Vol. 66 (september 2022) , p. 77-84  
Registro completo - Creative Commons
25.
12 p, 815.7 KB Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response / Ciriaco, Nikaoly (Hospital del Mar (Barcelona, Catalunya)) ; Zamora, Esther (Hospital Universitari Vall d'Hebron) ; Escrivá-de-Romaní, Santiago (Hospital Universitari Vall d'Hebron) ; Miranda Gómez, Ignacio (Hospital Universitari Vall d'Hebron) ; Jiménez Flores, José (Vall d'Hebron Institut d'Oncologia) ; Saura, Cristina (Hospital Universitari Vall d'Hebron) ; Sloane, Hillary ; Starus, Anna ; Fredebohm, Johannes ; Georgieva, Lucy ; Speight, Graham ; Jones, Frederick ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ; Espinosa-Bravo, Martín (Hospital Universitari Vall d'Hebron) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Although the standard of care is to perform surgery of primary breast cancer (BC) after neoadjuvant chemotherapy (NAC), for certain patients achieving clinical complete response (cCR) and pathologic complete response (pCR), omission of surgical treatment may be an option. [...]
2022 - 10.1177/17588359221139601
Therapeutic Advances in Medical Oncology, Vol. 14 (november 2022)  
Registro completo - Creative Commons
26.
14 p, 2.0 MB Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer : patient-reported outcomes from the FLIPPER trial / Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ; Martínez, M. Teresa ; Ramos, Manuel ; de la Cruz Merino, Luis ; Santaballa, Ana ; O'Connor, Miriam ; Martínez-Jañez, Noelia ; Moreno, Fernando ; Fernández, Isaura ; Virizuela, Juan Antonio ; Alarcón, Jesús ; de la Haba Rodríguez, Juan Rafael ; Sánchez-Rovira, Pedro ; Albacar, Cinta Rosa ; Bueno Muiño, Coralia ; Kelly, Catherine ; Casas, Maribel ; Bezares, Susana ; Rosell, Libertad ; Albanell Mestres, Joan (Hospital del Mar (Barcelona, Catalunya)) ; Universitat Autònoma de Barcelona
In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2− advanced breast cancer (ABC). [...]
2023 - 10.1177/17588359221148921
Therapeutic Advances in Medical Oncology, Vol. 15 (january 2023)  
Registro completo - Creative Commons
27.
8 p, 998.3 KB Evidence-based guidelines for hypofractionated radiation in breast cancer : conclusions of the Catalan expert working group / Eraso, Arantxa (Institut Català d'Oncologia (Girona, Catalunya). Radiation Oncology Department) ; Sanz, Javier (Hospital del Mar (Barcelona, Catalunya)) ; Mollà, Meritxell (Hospital Clínic i Provincial de Barcelona) ; Reyes López, Victoria (Hospital Universitari Vall d'Hebron) ; Pedro, Agustí (Institut d'Investigació Biomèdica Sant Pau) ; Arenas, Meritxell (Hospital Universitari Sant Joan de Reus (Tarragona)) ; Martinez, Evelyn (Institut Català d'Oncologia. Hospital Duran i Reynals. Servei d'Oncologia Radioteràpica) ; Ballester Alabau, Rosa (Institut Català d'Oncologia Badalona. Servei d'Oncologia Radioteràpica) ; Cambra, Maria José (Hospital General de Catalunya. Servei d'Oncologia Radioteràpica) ; García, Virginia (Hospital Universitari Arnau de Vilanova) ; Prades, Joan Lluis (Pla Director d'Oncologia de Catalunya. Institut Català d'Oncologia. Hospital Duran i Reynals) ; Borras, Josep M. (Pla Director d'Oncologia de Catalunya. Institut Català d'Oncologia. Hospital Duran i Reynals) ; Algara, Manuel (Institut Hospital del Mar d'Investigacions Mèdiques)
Introduction: Daily, moderate hypofractionation has become standard treatment for breast cancer following breast-conserving surgery, although substantial variation exists in its use. This paper describes the generation of consensus-based recommendations for the utilisation of this therapy at the healthcare system level and compares these to American Society for Radiation Oncology (ASTRO) guidelines. [...]
2022 - 10.1007/s12094-022-02798-8
Clinical & Translational Oncology, Vol. 24 Núm. 8 (august 2022) , p. 1580-1587  
Registro completo - Creative Commons
28.
19 p, 2.3 MB B Cells in Breast Cancer Pathology / Li, Mengyuan (King's College London) ; Quintana, Angela (Vall d'Hebron Institut d'Oncologia) ; Alberts, Elena (The Francis Crick Institute) ; Hung, Miu Shing (King's College London) ; Boulat, Victoire (King's College London) ; Martí, Mercè (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Grigoriadis, Anita (School of Cancer and Pharmaceutical Sciences) ; Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí"
B cells in the tumour microenvironment and lymph nodes have affirmed their role in breast cancer pathology. Multiplex imaging, single cell, and spatial transcriptomics of cancer patients' breast carcinomas and lymph nodes have illustrated the diversity and spatial context of B cells in this disease. [...]
2023 - 10.3390/cancers15051517
Cancers, Vol. 15, Issue 5 (February 2023) , art. 1517  
Registro completo - Creative Commons

Artículos : Encontrados 134 registros   inicioanterior19 - 28siguientefinal  ir al registro:
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos